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Introduction
Gastroparesis is a chronic stomach motility disorder and is characterized by slow emptying of solids in the absence of mechanical obstruction. It is estimated that up to 4% of the population in the United States suffers from gastroparetic symptoms (Abell et al., 2006) . Gastroparesis can be diabetic, post-surgical, or idiopathic. Treatment options include dietary management, pharmacologic agents, and surgical procedures such as gastric electrical stimulation and feeding jejunostomy (Friedenberg and Parkman, 2007) .
MCP was approved by the FDA in 1979, and has been available as a generic drug for many years. To date, MCP is the only FDA approved drug for the treatment of gastroparesis (Smith and Ferris, 2003) .
MCP is a dopamine receptor antagonist. In addition to being commonly prescribed for management of gastroparesis, it is also widely used as an anti-emetic. It is associated with central nervous system side effects. Clinically, neurologic effects of MCP result in a broad spectrum of drug induced movement disorders . These can range from acute dystonic reactions and Parkinsonism to chronic tardive dyskinesia.
MCP follows linear pharmacokinetics. It is administered orally, and is rapidly absorbed (Bateman, 1983) . It is not highly protein bound (fraction of drug unbound in plasma = 0.6) and distributes rapidly (volume of distribution = 2.2 -3.4 L/kg upon an IV dose, with alpha-phase half life of 5 -21 minutes) (Bateman, 1983) . Elimination of the unchanged drug (fraction of drug eliminated unchanged in urine = 0.2) as well as its metabolites is predominantly via urine, and its elimination half life is 5 -6 hours.
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6 MCP is extensively metabolized in humans. Metabolism has been thought to be predominantly via conjugation to sulfated and glucuronidated metabolites, although oxidative metabolites are also known (Bakke and Segura, 1976; Bateman, 1983; Desta et al., 2002; Yu et al., 2006) . Although MCP has been prescribed for decades, its exact metabolic profile in humans remains to be elucidated. While older reports state that a sulfated metabolite predominates, recent in silico and in vitro studies have noted major oxidative metabolites (Bakke and Segura, 1976; Bateman, 1983; Desta et al., 2002; Yu et al., 2006) . Cytochrome P450 2D6 (CYP2D6) is thought to catalyze MCP oxidation (Desta et al., 2002) . Relative contribution of other CYP isozymes and identity of specific conjugating enzymes is as yet unknown.
Characterizing the metabolic profile of a drug is critical in understanding its pharmacokinetics as well as its adverse effect profile. Identifying the specific enzymes responsible for drug metabolism further enables prediction of drug-drug interactions and inter-individual variability due to enzyme polymorphisms. These are poorly studied aspects of MCP. The present study sought to identify metabolites of MCP in humans. To this end, human urine samples were collected and analyzed after oral MCP administration. In vitro incubations were additionally carried out to identify human metabolites in hepatic subcellular fractions, and to corroborate in vivo findings.
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Center at Temple University Hospital for the duration of the study. Subjects were fasted overnight, and a baseline urine sample was collected before drug administration. Subjects were administered a single oral dose of 20 mg MCP (Reglan®) with 100 ml water. This was followed by a standard meal 30 minutes later, and at regular intervals until the end of the study. Urine was collected until 24 hours post-dose. Urine samples were collected in 1000 ml capacity Nalgene glass bottles, and were stored immediately upon collection at -20 o C until further analysis. For LC-MS/MS analysis, 5 ml urine sample was thawed and centrifuged at 14000 rpm for 10 minutes. The supernatant was directly analyzed.
In vitro incubations
CYP incubations
CYP-mediated metabolism of MCP was characterized in HLM using methods previously described (Ung et al., 2009) . Briefly, incubation preparations contained HLM (0.5 mg/ml) with a NADPH regenerating system (final concentrations of components in reactions are; 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 0.4 U/ml glucose-6-phosphate dehydrogenase, and 3.3 mM magnesium chloride) and 50 mM potassium phosphate buffer (pH 7.4). To initiate reactions, MCP (1 mM final concentration) was added for a total incubation volume of 500 μ l and incubated at 37°C for 5 hours. High substrate concentration was intended to avoid substrate depletion. Because enzyme kinetics were not evaluated, incubations were not limited to initial-rate conditions but were conducted for high metabolite yield. Reactions were terminated by addition of 100 μ l ice cold acetonitrile. Reactions were then centrifuged at 14000 rpm for 5 minutes and the supernatant collected for further analysis on HPLC.
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Glucuronidation reactions were conducted either as one-step UGT incubations, or twostep mixed CYP+UGT incubations. For one-step glucuronidation (Iwuchukwu and Nagar, 2008) incubations in a total volume of 500 µl, contained HLM (0.5 mg/ml), 1 mM MCP, 5 mM MgCl 2 , 10 µg/ml alamethicin (pore-forming agent to 'activate' latent UGTs), and 5 mM UDPGA in the reaction buffer 0.1 M Tris-HCl (pH 7.4 at 37˚C). After 1 hour, the reaction was terminated with 50 µL ice cold acetonitrile, and prepared for further analysis. For the two-step CYP+UGT incubations, a total volume of 500 µl containing 0.5 mg/ml HLM, 1mM MCP, and NADPH regenerating system in 50 mM potassium phosphate buffer (pH 7.4) was first incubated at 37˚C for 3 hours prior to the addition of alamethicin (10µg/ml) and UDPGA (5mM) for further incubation overnight at 37˚C. Because enzyme kinetics were not evaluated, incubations were not limited to initial-rate conditions. The reaction was terminated the next morning by addition of 100 µl of ice cold acetonitrile and centrifuged at 14000 rpm for 5 minutes. The supernatant was collected for further analysis on LC-MS/MS.
SULT incubations
Sulfation reactions were conducted using human liver cytosol (HLC). Briefly, using a modified assay (Ung and Nagar, 2007) , a total incubation volume of 500 µl contained 1 mg/ml HLC, 1mM MCP, and 4 mM PAPS in 10 mM potassium phosphate pH (6.5).
Incubations were carried out for 3 hours at 37˚C and then terminated with ice cold acetonitrile (200 µl). Because enzyme kinetics were not evaluated, incubations were not limited to initial-rate conditions. The sample was centrifuged at 14000 rpm for 5 minutes and the supernatant was collected for analysis on LC-MS/MS.
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HPLC instrumentation and metabolite detection
Samples from in vitro incubations were initially analyzed by reversed-phase highperformance liquid chromatography using a slightly modified method (Desta et al., 2002) . The HPLC system (Hewlett-Packard 1100 series; Agilent Technologies, Santa Clara, CA) components were a vacuum degasser, a quaternary pump, an autosampler, a 20% acetonitrile and 80% buffer (100 mM sodium acetate plus 0.05% v/v triethylamine, pH adjusted to 7.0 with acetic acid), at a flow rate of 1.0 ml/minute. The supernatants (100 ul injection) of CYP-mediated reactions were analyzed and two separate metabolite peaks were detected at 20.7 and 22.9 minutes, respectively. Fractions containing each respective metabolite were collected for structural elucidation by LC-MS/MS. Similarly, supernatants from other in vitro incubations were initially run on the HPLC-UV assay, and all putative metabolite peaks were further tested by LC-MS/MS.
LC-MS n method for metabolite identification
A sensitive LC-MS n method was developed for identification of MCP metabolites, by modification of a previously reported method (Gunduz et al., 2010) . Urine collected over a period of 24 hours was aliquoted and centrifuged at 6440 x g for 5 minutes prior to analysis. The respective supernatants were removed and transferred to 1 mL conical 
Comparison of MCP urinary metabolites across subjects
Urinary MCP as well as metabolite absolute peak areas were compared across all subjects (n=8) for inter-subject variability in each metabolite's formation. It was not possible to compare relative formation of the different metabolites because synthetic metabolite standards were not available. The MS signals obtained for each chemical moiety could not be compared across chemicals due to lack of equimolar responses across the chemical matter. Therefore, for each metabolite, the fold-variability was calculated by normalizing the highest absolute peak area to the lowest absolute peak area for that metabolite among 8 subjects.
This article has not been copyedited and formatted. The final version may differ from this version. 
Structural rationalization of M2
A peak corresponding to m/z 380 was observed at 5.7 minutes (Figure 2A ). CID of m/z 380 (M2), upon ESI at a collision energy of 35 revealed a base peak ion of m/z 300, corresponding to the protonated molecular ion of MCP. In addition m/z 227, a fragment ion that corresponded MCP sans the ethyl amine moiety, was also observed. A peak at m/z 300 was also observed as a single peak in a neutral loss scan of 80 amu, a diagnostic loss of the sulfonic acid group. FTMS based accurate mass measurement confirmed M2
to be a MCP sulfate ( Figure 4B ). Comparison with in vitro SULT incubations in HLC corroborated these findings.
Structural rationalization of M3
An N-des-ethyl metabolite of MCP was observed at 6.2 minutes (Figure 2A Neither was a peak corresponding to MCP, m/z 300 observed at 6.5 minutes, nor did MS 2 spectrum reveal fragments corresponding to the unchanged 4-amino-5-chloro-2-methoxybenzoyl moiety of MCP. This data collectively points toward M4 being an oxidation on a carbon atom, and not a heteroatom i.e. the aromatic amino group.
Structural rationalization of M5
M5 was identified to be an oxidative metabolite of MCP, resulting from an oxidative deamination of the diethyl amine moiety followed by subsequent oxidation. 
Structural rationalization of M6 and M8
In in vitro incubations, M6 and M8 were formed only in two-step CYP/UGT incubations values, the mass accuracy value (δppm) for M10 was found to be -1.5 ppm ( Figure 5F ).
Therefore, M10 was determined to be a stable nitro metabolite of MCP.
Inter-subject variability in MCP metabolism
A total of 8 individuals were evaluated for urinary MCP and metabolites M1-M5 levels in a full urine (24-h) sample. As depicted in Figure 6 , there was high inter-subject variability among the subjects for each chemical moiety. The most marked variability was found in levels of metabolite M2 (21-fold) and metabolite M3 (16-fold).
Discussion
MCP is the only FDA-approved drug for patients with gastroparesis. MCP is associated with neurologic side effects due to its action on central dopaminergic receptors. These neurologic effects consist of a broad spectrum of syndromes known as drug induced movement disorders (DIMDs) . DIMDs can be acute or chronic, and vary in their severity. MCP-induced DIMDs accounted for 8% of all movement disorders in a study recruiting 125 patients prescribed neuroleptic drugs (Miller and Jankovic, 1990) . In a bigger study involving 434 tardive dyskinesia patients, MCP was found to be one of the most common medications associated with tardive dyskinesia (Kenney et al., 2008) . It therefore becomes critical to understand the disposition of MCP, and to determine its metabolites and their activity/toxicity in humans. Even if all MCP metabolites are inactive, enzyme induction or inhibition with co-administered drugs might affect the disposition of MCP and therefore its efficacy / side effect profile.
Further, variability in MCP efficacy and toxicity might be due to genetic variability in its metabolizing enzymes, and knowledge of MCP metabolism is necessary to elucidate these effects.
The pharmacokinetics of MCP have been characterized in humans and other mammalian species (Bakke and Segura, 1976; Bateman, 1983; McDermed et al., 1985; Lamparczyk et al., 2001; Kim et al., 2002; Vlase et al., 2006; Zaki et al., 2006) . Significant interspecies differences have been reported in MCP metabolism (Bakke and Segura, 1976; Cowan et al., 1976; Bateman, 1983) . About 80% of MCP is reportedly metabolized in humans (Bateman, 1983) . However, to our knowledge, its metabolism in humans has not This article has not been copyedited and formatted. The final version may differ from this version. been described in detail. Conjugated metabolites (an N-sulfate and a glucuronide) and an oxidative deamination product (labeled M5 in the present study) have been reported in humans (Bateman, 1983) . Conjugated metabolites were previously discerned indirectly by subjecting samples to deconjugation reactions, and the exact structure of conjugates was not described (Bateman et al., 1980) . A recent study reported a deethylated MCP metabolite (labeled M3 in the present study) in vitro (Desta et al., 2002) , but this metabolite was not reported in vivo. Finally, an arylhydroxyamino metabolite was reported in vitro (Yu et al., 2006) and in human urine (Maurich et al., 1995) , but was not detected in the present study. However, this metabolite might be a precursor for the N-Oglucuronide (M1) which we report for the first time. M1 is formed by sequential metabolism via CYP followed by UGT. Thus, for the 5 in vivo metabolites (Table 1) we report here (M1 -M5), metabolites M2 and M5, have been previously reported in vivo.
Metabolites M1 and M4 are reported here for the first time.
For the 5 additional metabolites (Table 1) we observed in vitro (M6 -M10), metabolites M6, M8, M9 and M10 have never been reported. Metabolite M7 was reported in vivo but it is possible that an N-O-glucuronide (M1) may have been mistaken for an Nglucuronide (M7) due to the use of deconjugation to identify glucuronides, and the lack of sophisticated MS capability in earlier studies. We observed M7 only in vitro and not in human urine. It is interesting to note that a stable carbamic acid metabolite of MCP was identified in vitro in HLM incubations (M9). It is possible that carrying out MCP incubations in a NaHCO 3 buffer may lead to increased formation of this metabolite, or may even result in subsequent N-carbamoyl glucuronide formation (Gunduz et al., 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. We observed metabolites M6 -M10 only in vitro but not in human urine. It is possible that these metabolites are formed in vitro due to the relatively high drug concentration that liver preparations are directly exposed to, a scenario that might not occur in vivo. It is also possible that these metabolites are formed to a very small extent in vivo, and were therefore not detected. Finally, only human urine samples were collected in the present study and it is possible that some metabolites are excreted via non-renal pathways and therefore were not detected in human urine. This first study with noninvasive sample collection will form the basis of future work where plasma levels of circulating metabolites will be discerned.
The goal of the present study was identification of all human urinary MCP metabolites.
Therefore, it was a small study recruiting only 8 healthy male subjects. Because MCP metabolites were not available as synthetic standards, it was not possible to determine the extent of metabolite formation, or to compare metabolites and determine quantitatively major metabolites. The average elimination half-life of MCP is about 5 hours (Bateman, 1983; Lamparczyk et al., 2001; Vlase et al., 2006) , therefore full urine collection for 5 DMD #33357
half-lives (24 h) was conducted. In the urine samples, MCP levels were found to be 3.6-fold variable in the 8 subjects. There was high variability in all the metabolites (M1 -M5; Figure 6 ), with the M2 (21-fold) and M3 (16-fold) being the most variable.
Metabolite M2 was reported to be a major metabolite of MCP (Bateman, 1983) , and is a sulfated conjugate. Genetic variability in human sulfotransferases (SULTs) is well understood (Nowell and Falany, 2006) , and identification of specific SULT isozymes that catalyze MCP sulfation in future studies will shed light on the role of SULT pharmacogenetics in variable MCP metabolism. Metabolite M3 was reported to be formed via human cytochrome P450 CYP2D6 in vitro (Desta et al., 2002) . CYP2D6 is a well known highly polymorphic enzyme, and this genetic variation might contribute to Based on these m/z values, the mass accuracy value (δppm) for M10 was found to be -1.5 ppm. 
